This position paper replaces the 2016 WHO position paper concerning the first licensed dengue vaccine, CYD-TDV. In November 2017, results of a retrospective analysis of data from clinical trials, using a new serological assay, became available. The assay enabled classification of trial participants according to their dengue serostatus prior to receipt of the first vaccine dose. These data revealed an excess risk of severe dengue in seronegative vaccine recipients compared to seronegative non-vaccinated individuals, while confirming long-term protection in seropositive individuals. In view of these findings, SAGE provided revised recommendations in April 2018, on which this position paper is based.

  • Position paper
  • Dengue